Relapsed Myeloma: Navigating Post-BCMA Therapy Failure
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Relapsed Myeloma: Navigating Post-BCMA Therapy Failure
-
Narrated by:
-
By:
About this listen
Join us for an insightful discussion with Drs. Natalia Neparidze and Saad Z. Usmani as we explore treatment strategies for relapsed multiple myeloma following BCMA-targeted therapy failure. With CAR T-cell therapy and bispecific antibodies revolutionizing myeloma treatment, clinicians are now faced with new challenges as patients relapse after BCMA-directed therapies.
Through the case of a 62-year-old woman who relapsed one year post-BCMA CAR T-cell therapy, we will discuss mechanisms of resistance, treatment sequencing, and the role of novel agents like selinexor-pomalidomide-dexamethasone. This episode will provide hematologists with practical strategies to navigate post-BCMA treatment failure and optimize patient outcomes.
Learning Objectives
- Understand mechanisms of resistance and progression following BCMA-targeted therapy.
- Explore non-BCMA treatment options, including alternative targets and novel agents.
- Recognize key factors influencing treatment selection and patient management.